Tonix Pharmaceuticals To Present New Data On Tonmya Suggesting Activity For Improvement In Fibromyalgia-Associated Depression Severity In An Oral Presentation At ASCP Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals presented new data on Tonmya, showing its potential to improve fibromyalgia-associated depression severity. The data was presented at the ASCP Annual Meeting, and the company plans to submit a New Drug Application to the FDA in the second half of 2024.
June 03, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals presented new data on Tonmya, indicating its potential to improve fibromyalgia-associated depression. The company plans to submit a New Drug Application to the FDA in the second half of 2024.
The presentation of positive data on Tonmya and the upcoming NDA submission are likely to boost investor confidence and positively impact TNXP's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100